Interview with Victor Bulto, President, US, Novartis

In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients. Victor Bulto, President, Novartis Novartis FDA Institute for Clinical and Economic Review (ICER) American Heart Association (AHA) Inflation Reduction Act (IRA) Pharmacy Benefit Manager (PBM) Medicare Medical terminology referenced in this episode: Cell therapy: CART-T  Radioligand therapy RNA Entresto Molecular glues Targeted protein degradation Antisense oligonucleotides Small interfering RNAs: siRNAs LDL cholesterol COVID Hematological malignancies Refractory autoimmune diseases Questions or comments?Email us at [email protected] us on social media! Follow us on X, LinkedIn, YouTube and Threads.